2017
Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC
Nathavitharana RR, Shi CX, Chindelevitch L, Calderon R, Zhang Z, Galea JT, Contreras C, Yataco R, Lecca L, Becerra MC, Murray MB, Cohen T. Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2017, 23: 1887-1890. PMID: 29048297, PMCID: PMC5652442, DOI: 10.3201/eid2311.170077.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisHost Mycobacterium tuberculosis diversityMultidrug-resistant TBInfectious Diseases journal - CDCPulmonary TB patientsPulmonary tuberculosis infectionTB patientsTuberculosis infectionPolyclonal infectionsSimple infectionMultidrug resistanceInfectionPatientsTuberculosisPrevalenceDiagnosis
2014
Geographical heterogeneity of multidrug-resistant tuberculosis in Georgia, January 2009 to June 2011.
Jenkins HE, Gegia M, Furin J, Kalandadze I, Nanava U, Chakhaia T, Cohen T. Geographical heterogeneity of multidrug-resistant tuberculosis in Georgia, January 2009 to June 2011. Eurosurveillance 2014, 19 PMID: 24679722, PMCID: PMC4090679, DOI: 10.2807/1560-7917.es2014.19.11.20743.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBMDR-TB risk factorsTB casesRisk factorsMDR-TB incidenceMDR-TB riskMDR-TB transmissionMDR-TB casesMultidrug-resistant tuberculosisTreatment-naïve individualsMDR-TB burdenTuberculosis casesHigh riskTargeted interventionsSurveillance dataGeographical heterogeneityRegression modellingInterventionRiskRural areasCasesTuberculosisIncidencePercentage
2012
Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLOS Medicine 2012, 9: e1001347. PMID: 23185139, PMCID: PMC3502465, DOI: 10.1371/journal.pmed.1001347.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBCost-effectiveness ratioInitial diagnosisXpert MTB/RIF testMTB/RIF testXpert MTB/RIFIntroduction of XpertTB natural historyTB-HIV coinfectionMultidrug-resistant tuberculosisHigh HIV prevalenceMTB/RIFHealth system costsImplementation of XpertHealth impactsPopulation health impactCost-effectiveness resultsLong-term transmission dynamicsWorld Health OrganizationAntiretroviral therapyTB casesTB deathsTB morbidityHIV prevalenceRIF testModeling the Dynamic Relationship Between HIV and the Risk of Drug-Resistant Tuberculosis
Sergeev R, Colijn C, Murray M, Cohen T. Modeling the Dynamic Relationship Between HIV and the Risk of Drug-Resistant Tuberculosis. Science Translational Medicine 2012, 4: 135ra67. PMID: 22623743, PMCID: PMC3387814, DOI: 10.1126/scitranslmed.3003815.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBDrug-resistant tuberculosisDrug-resistant TBHIV-seropositive individualsHIV statusTB patientsLatent Mycobacterium tuberculosis infectionIndividual HIV statusIncident HIV infectionMultidrug-resistant tuberculosisMycobacterium tuberculosis infectionEffects of HIVCross-sectional studyDrug-resistant formsRise of HIVIndividual-level associationsAcquisition of resistanceAverage CD4HIV infectionResistance-conferring mutationsTB controlTuberculosis infectionResistant tuberculosisTB drugsHIV epidemic